Rani Therapeutics Holdings (RANI) Minority Interest (2021 - 2026)

Rani Therapeutics Holdings has reported Minority Interest for 6 years, with the latest figure at $8.8 million in Q2 2026.

• On a quarterly basis, Minority Interest rose 344.58% year-over-year to $8.8 million in Q2 2026; TTM through Jun 2026 was $8.8 million, a 344.58% increase from a year earlier, with the FY2025 full-year figure at $8.5 million, up 466.42% from the prior year.
• Minority Interest was $8.8 million for Q2 2026 at Rani Therapeutics Holdings, up from $7.1 million in the prior quarter.
• The five-year high for Minority Interest was $57.3 million in Q1 2022, with the low at -$4.1 million in Q3 2025.
• Average Minority Interest over 5 years is $16.8 million, with a median of $8.6 million recorded in 2025.
• The largest YoY upside for Minority Interest was 466.42% in 2025 against a maximum downside of 254.92% in 2025.
• Over 5 years, Minority Interest stood at $37.1 million in 2022, then sank by 66.14% to $12.6 million in 2023, then slumped by 88.07% to $1.5 million in 2024, then jumped by 466.42% to $8.5 million in 2025, then advanced by 2.93% to $8.8 million in 2026.
• The last three Minority Interest figures came in at $8.8 million (Q2 2026), $7.1 million (Q1 2026), and $8.5 million (Q4 2025), per Business Quant data.